Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
Source abstract
Abstract
Abstract Despite decades of research, glioblastoma (GBM) remains invariably fatal among all forms of cancers. The high level of inter‐ and intratumoral heterogeneity along with its biological location, the brain, are major barriers against effective treatment. Molecular and single cell analysis identifies different molecular subtypes with varying prognosis, while multiple subtypes can reside in the same tumor. Cellular plasticity among different subtypes in response to therapies or during recurrence adds another hurdle in the treatment of GBM. This phenotypic shift is induced and sustained by activation of several pathways within the tumor itself, or microenvironmental factors. In this review, the dynamic nature of cellular shifts in GBM and how the tumor (immune) microenvironment shapes this process leading to therapeutic resistance, while highlighting emerging tools and approaches to study this dynamic double‐edged sword are discussed.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Glioma Diagnosis and Treatment · Immune cells in cancer · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Experimental Therapeutics and Molecular Imaging Unit Department of Neurology Neuro‐Oncology Division Massachusetts General Hospital and Harvard Medical School Boston MA 02129 USA
Department of Health Technology and Informatics The Hong Kong Polytechnic University Hong Kong 999077 China
Funding
National Institutes of Health · National Cancer Institute · National Institute of Neurological Disorders and Stroke
References (100+)
Show source-provided references
1. Kinnersley B. · Cancer Epidemiol., Biomarkers Prev. · 2018 · 27 · 41810.1158/1055-9965.EPI-17-1080 ↗
2. Filbin M. · Semin. Neurol. · 2018 · 38 · 12110.1055/s-0038-1635106 ↗
3. 10.4065/82.10.127110.4065/82.10.1271 ↗
4. Katsigiannis S. · Radiat. Oncol. · 2019 · 14 · 7310.1186/s13014-019-1272-6 ↗
5. 10.1016/S1470-2045(09)70025-710.1016/S1470-2045(09)70025-7 ↗
6. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
7. 10.1056/NEJMoa04333110.1056/NEJMoa043331 ↗
8. 10.1093/neuonc/not04010.1093/neuonc/not040 ↗
9. 10.1093/neuonc/noz15010.1093/neuonc/noz150 ↗
10. 10.1124/pr.117.01494410.1124/pr.117.014944 ↗
11. 10.1093/brain/awz04410.1093/brain/awz044 ↗
12. 10.1016/j.ccr.2009.12.02010.1016/j.ccr.2009.12.020 ↗
13. 10.1038/nrclinonc.2017.12210.1038/nrclinonc.2017.122 ↗
14. 10.1016/j.ccell.2017.06.00310.1016/j.ccell.2017.06.003 ↗
15. 10.3390/cells811131210.3390/cells8111312 ↗
16. 10.1016/j.celrep.2016.11.05610.1016/j.celrep.2016.11.056 ↗
17. 10.3390/ijms2011274610.3390/ijms20112746 ↗
18. 10.1080/15384101.2017.138897210.1080/15384101.2017.1388972 ↗
19. 10.1038/s41580-018-0080-410.1038/s41580-018-0080-4 ↗
20. 10.1002/1878-0261.1209610.1002/1878-0261.12096 ↗
21. 10.1007/s00018-017-2714-710.1007/s00018-017-2714-7 ↗
22. 10.1016/j.ccr.2006.02.01910.1016/j.ccr.2006.02.019 ↗
23. 10.1016/j.ccr.2012.08.02410.1016/j.ccr.2012.08.024 ↗
24. 10.1073/pnas.140583911110.1073/pnas.1405839111 ↗
25. 10.1038/cddis.2017.36810.1038/cddis.2017.368 ↗
26. 10.1016/j.cell.2019.06.02410.1016/j.cell.2019.06.024 ↗
27. 10.1016/j.canlet.2015.01.01010.1016/j.canlet.2015.01.010 ↗
28. 10.1073/pnas.122147811010.1073/pnas.1221478110 ↗
29. 10.1002/stem.111410.1002/stem.1114 ↗
30. 10.1242/dev.09532310.1242/dev.095323 ↗
31. 10.1038/ng.359010.1038/ng.3590 ↗
32. 10.1016/j.ccr.2014.06.00510.1016/j.ccr.2014.06.005 ↗
33. 10.1038/nature0871210.1038/nature08712 ↗
34. 10.1101/gad.176800.11110.1101/gad.176800.111 ↗
35. 10.1016/j.ccr.2013.08.00110.1016/j.ccr.2013.08.001 ↗
36. 10.1038/cddis.2014.39510.1038/cddis.2014.395 ↗
37. 10.1002/1878-0261.1262310.1002/1878-0261.12623 ↗
38. 10.1007/s11060-016-2145-610.1007/s11060-016-2145-6 ↗
39. Luo D. · Int. J. Oncol. · 2018 · 53 · 2067
40. 10.3892/ijo.2017.395410.3892/ijo.2017.3954 ↗
41. 10.1080/15384047.2015.102870210.1080/15384047.2015.1028702 ↗
42. Hasan T. · Cell Death Dis. · 2019 · 10 · 29210.1038/s41419-019-1387-6 ↗
43. 10.1186/s12929-018-0464-y10.1186/s12929-018-0464-y ↗
44. 10.1007/s11060-010-0261-210.1007/s11060-010-0261-2 ↗
45. 10.18632/oncotarget.2459510.18632/oncotarget.24595 ↗
46. 10.1038/ncomms1288510.1038/ncomms12885 ↗
47. Liu Q. · J. Exp. Clin. Cancer Res. · 2019 · 38 · 35810.1186/s13046-019-1370-1 ↗
48. Iwata R. · Neuro Oncol. · 2020 · 22 · 333
49. 10.1016/j.ccell.2016.01.00510.1016/j.ccell.2016.01.005 ↗
50. 10.3390/cells709012510.3390/cells7090125 ↗
51. 10.1016/j.celrep.2019.01.07610.1016/j.celrep.2019.01.076 ↗
52. 10.1371/journal.pone.022271710.1371/journal.pone.0222717 ↗
53. 10.1158/0008-5472.CAN-17-038810.1158/0008-5472.CAN-17-0388 ↗
54. 10.3390/cancers1111163510.3390/cancers11111635 ↗
55. 10.3390/cancers1012051210.3390/cancers10120512 ↗
56. 10.1158/0008-5472.CAN-14-333110.1158/0008-5472.CAN-14-3331 ↗
57. Li Z. · Am. J. Cancer Res. · 2019 · 9 · 699
58. 10.1038/nrg.2016.1310.1038/nrg.2016.13 ↗
59. O'leary K. · Curr. Cancer Drug Targets · 2018 · 18 · 8910.2174/1568009617666170203162556 ↗
60. Zhang B. · Clin. Epigenet. · 2020 · 12 · 4710.1186/s13148-020-00835-3 ↗
61. Urdiciain A. · Int. J. Oncol. · 2019 · 54 · 1797
62. 10.1158/0008-5472.CAN-19-122910.1158/0008-5472.CAN-19-1229 ↗
63. 10.1038/s41388-020-1161-310.1038/s41388-020-1161-3 ↗
64. 10.1016/j.gene.2015.09.08010.1016/j.gene.2015.09.080 ↗
65. 10.1186/s13148-019-0763-510.1186/s13148-019-0763-5 ↗
66. 10.18632/oncotarget.2131110.18632/oncotarget.21311 ↗
67. 10.1002/ijc.3236010.1002/ijc.32360 ↗
68. 10.1186/s13046-019-1341-610.1186/s13046-019-1341-6 ↗
69. Kan S. · Oncol. Lett. · 2019 · 18 · 1679
70. Zhang M. · Exp. Ther. Med. · 2019 · 18 · 2140
71. 10.1158/1541-7786.MCR-16-049410.1158/1541-7786.MCR-16-0494 ↗
72. 10.1158/0008-5472.CAN-09-224910.1158/0008-5472.CAN-09-2249 ↗
73. 10.1038/cdd.2011.14410.1038/cdd.2011.144 ↗
74. Zhang Y. · Oncol Lett. · 2018 · 15 · 762510.3892/ol.2018.8296 ↗
75. Chen W. · Int. J. Oncol. · 2018 · 52 · 485
76. 10.1016/j.bbrc.2015.11.02510.1016/j.bbrc.2015.11.025 ↗
77. 10.1016/j.phrs.2019.10439010.1016/j.phrs.2019.104390 ↗
78. 10.1007/s11060-018-2973-710.1007/s11060-018-2973-7 ↗
79. 10.1111/1759-7714.1261210.1111/1759-7714.12612 ↗
80. Feng S. · Mol. Med. Rep. · 2018 · 17 · 2964
81. 10.18632/oncotarget.1553110.18632/oncotarget.15531 ↗
82. 10.3892/ijo.2017.394710.3892/ijo.2017.3947 ↗
83. 10.1111/jcmm.1482910.1111/jcmm.14829 ↗
84. 10.1038/s41419-019-1948-810.1038/s41419-019-1948-8 ↗
85. 10.18632/oncotarget.1599110.18632/oncotarget.15991 ↗
86. Fu Q. · Biosci. Rep. · 2019 · 39
87. Gabrusiewicz K. · JCI insight · 2016 · 110.1172/jci.insight.85841 ↗
88. 10.1016/j.celrep.2017.10.03010.1016/j.celrep.2017.10.030 ↗
89. 10.1158/2159-8290.CD-19-032910.1158/2159-8290.CD-19-0329 ↗
90. 10.1158/2326-6066.CIR-13-002810.1158/2326-6066.CIR-13-0028 ↗
91. 10.1371/journal.pone.004333910.1371/journal.pone.0043339 ↗
92. 10.1089/scd.2011.066010.1089/scd.2011.0660 ↗
93. 10.1111/nan.1242810.1111/nan.12428 ↗
94. 10.1080/2162402X.2019.165536010.1080/2162402X.2019.1655360 ↗
95. 10.1186/s40478-019-0803-610.1186/s40478-019-0803-6 ↗
96. 10.1158/1078-0432.CCR-13-055110.1158/1078-0432.CCR-13-0551 ↗
97. 10.1016/j.ajpath.2012.01.04010.1016/j.ajpath.2012.01.040 ↗
98. 10.1038/s41582-018-0025-810.1038/s41582-018-0025-8 ↗
99. 10.1007/s00401-015-1529-610.1007/s00401-015-1529-6 ↗
100. 10.1074/jbc.M115.66403710.1074/jbc.M115.664037 ↗